SC
SCL Science Inc.
246960 | KO
Overview
Corporate Details
- ISIN(s):
- KR7246960009
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 영등포구 선유로13길 25 에이스하이테크시티 2차 1209호, 서울특별시
- Website:
- https://sclscience.com/en
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-11 00:00 |
M&A Activity
타법인주식및출자증권취득결정(자율공시)
|
Korean | 16.2 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-08-14 00:00 |
Regulatory Filings
단일판매ㆍ공급계약체결
|
Korean | 10.4 KB | ||
| 2025-08-14 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 13.7 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 114.2 KB | ||
| 2025-07-28 00:00 |
Delisting Announcement
주권매매거래정지 (영업양수도)
|
Korean | 4.8 KB | ||
| 2025-07-28 00:00 |
M&A Activity
주요사항보고서(영업양수결정)
|
Korean | 18.8 KB | ||
| 2025-07-21 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(무상증자결정)
|
Korean | 15.0 KB |
Automate Your Workflow. Get a real-time feed of all SCL Science Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SCL Science Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SCL Science Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing a local drug delivery platform to treat KRAS-driven cancers and solid tumors.
United States of America
SLXN
United States of America
SLXN
South Korea
215600
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden
SIMRIS
Sweden
SIMRIS
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
United States of America
SKYE
United States of America
SKYE
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
Provides pharma lab services, clinical trial analysis, and innovative diagnostic products.
South Korea
246250
South Korea
246250
A bioscience group offering clinical testing, supplements, and cosmetics for pharma/food industries.
Japan
2385
Japan
2385
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
United States of America
SLDB
Developing a high-precision, minimally invasive therapy for internal tumors like prostate cancer.
Sweden
SPEC
Sweden
SPEC
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
Sweden
SPRINT
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
United States of America
SPRB